Study of XNW5004 plus enzalutamide for advanced prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new drug, XNW5004, combined with enzalutamide for men with metastatic castration-resistant prostate cancer that has progressed despite other treatments. It aims to see if this combination can slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have metastatic prostate cancer that is still growing even with hormone therapy.
- You must have tried at least one other hormone therapy (like abiraterone) and it stopped working.
- You cannot have had enzalutamide before (except in certain parts of the study).
- You cannot have had chemotherapy for this type of cancer.
- You must have good general health and organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new oral drug, XNW5004, for men with advanced prostate cancer that has spread or stopped responding to standard treatments. It may be given alone or with other therapies like abiraterone, enzalutamide, or chemotherapy, and aims to find better ways to control the disease.
This trial tests a new experimental drug (TYK-00540) combined with enzalutamide, an approved hormone therapy, for men with advanced prostate cancer that has spread and no longer responds to standard hormone therapy. The goal is to see if the combination can slow cancer growth better than current options.
This trial tests whether adding the drug SX-682 to enzalutamide can help men whose prostate cancer has stopped responding to other hormone treatments. You may be eligible if your cancer is growing despite treatment with abiraterone, darolutamide, apalutamide, or enzalutamide.
This study tests an experimental drug called XNW34017 in people with advanced or metastatic solid tumors, especially small cell lung cancer and prostate cancer that have progressed despite prior treatments. The goal is to see if the drug is safe and effective for these cancers.
This trial tests two new drugs (QLC5508 and QLH12016) alone or together with other treatments for prostate cancer that has spread to other parts of the body. It may be an option if standard treatments have stopped working or caused side effects.
This study tests a new drug called CP-PCA07 combined with enzalutamide for men whose prostate cancer has stopped responding to enzalutamide or abiraterone. The goal is to see if the combination is safe and can help control the cancer.
Hear when a new Metastatic Castrate-Resistant Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.